n and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
For Adults Whose CRC Has Spread to Other Parts of the Body (Metastatic), Has Progressed After Treatment With a Fluoropyrimidine, Oxaliplatin, and Irinotecan, and is dMMR or MSI-H (10 of 12)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
For People 12 Years of Age and Older Whose CRC Has Spread to Other Parts of the Body (Metastatic), Has Progressed After Treatment With a Fluoropyrimidine, Oxaliplatin, and Irinotecan, and Is dMMR or MSI-H (11 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
For Adults With classical Hodgkin Lymphoma Whose Cancer Has Come Back or Spread After an Autologous Stem Cell Transplant and Treatment With Adcetris® (brentuximab vedotin) or After 3 or More Kinds of Treatment Including an Autologous Stem Cell Transplant (12 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin Lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the drug brentuximab vedotin (Adcetris®) before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer, or in children younger than 18 years of age for the treatment of any other cancers. |
